INO 4201
Alternative Names: INO-4201Latest Information Update: 19 Apr 2023
At a glance
- Originator Inovio Pharmaceuticals
- Developer Inovio Pharmaceuticals; University Hospitals of Geneva
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ebola virus infections
Most Recent Events
- 17 Apr 2023 Immunogenicity data from a phase Ib trial in Ebola virus infection released by Inovio Pharmaceuticals
- 28 Jan 2023 No recent reports of development identified for phase-I development in Ebola-virus-infections(Combination therapy, Prevention) in USA (IM, Injection)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Ebola-virus-infections(Combination therapy, Prevention) in USA (Intradermal, Injection)